Danone-Backed Biotech Platform Accelerates Fermentation Ingredient Scale-Up in France

Clermont-Ferrand, France — 01 October 2026

Danone, in partnership with Michelin, DMC Biotechnologies, and other entities, has inaugurated a €20 million industrial biotechnology platform in Clermont-Ferrand, France. Named the Biotech Open Platform, this facility is engineered to bridge the critical gap between laboratory development and commercial-scale production for fermentation-derived food ingredients. The platform offers capabilities for fermentation, purification, and bioprocess development, scalable from 10 grams to one metric tonne, with fermentation volumes up to 15m³.

The initiative directly tackles a significant hurdle in industrial biotechnology: moving promising innovations beyond the pilot stage to commercially viable volumes. This is particularly relevant for the development of proteins, enzymes, and other fermented ingredients, areas where supply chain robustness and consistent functionality at scale remain crucial for supplement manufacturers. According to Antoine de Saint-Affrique, CEO of Danone, this investment strengthens Europe’s biotechnology ecosystem by accelerating industrial scale-up and enhancing regional competitiveness.

Beyond merely adding capacity, the platform is designed to provide the technical expertise and infrastructure necessary to overcome performance and stability challenges that often arise when scaling biotech-derived ingredients. Companies using the platform can produce sufficient quantities for application testing and validation, mitigating financial risks associated with full commercial production commitments. This shared infrastructure model, open to start-ups, established companies, and research organisations, addresses the need for greater fermentation capacity and de-risks ingredient procurement for supplement brands exploring alternative proteins and functional ingredients.

However, the broader commercial success of these ingredients depends on more than just scale-up capacity. Factors such as production costs, yield efficiencies, regulatory approvals, and successful integration into existing food manufacturing processes remain significant considerations. While the platform offers a pathway to industrialisation, manufacturers must still navigate market acceptance and ensure consumer confidence in these novel ingredients.

What this means for France

French manufacturers and brand owners gain a significant competitive edge through direct access to advanced, industrial-scale fermentation capabilities, potentially reducing external R&D costs and accelerating ingredient pipeline development. The Biotech Open Platform provides a domestic pathway for validating novel ingredients, addressing supply chain vulnerabilities, and ensuring compliance with EU food production standards for biotech-derived components. This infrastructure supports local innovation, potentially attracting foreign investment and positioning France as a leader in sustainable ingredient manufacturing, improving market access for new functional ingredients within Europe.

What this means for Europe

For European supplement manufacturers, this platform offers a strategic resource for diversifying ingredient sourcing, particularly for proteins and enzymes, reducing reliance on non-European suppliers. It creates a critical acceleration point for innovations in precision fermentation, allowing for faster transition from lab to market for novel ingredients that meet European regulatory standards. This investment directly supports the bloc's drive for greater self-sufficiency in food ingredient production, mitigating future supply chain disruptions and fostering regional scientific and commercial collaboration.

Many leading brands in this category are manufactured in partnership with Supplement Factory.